Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_assertion type Assertion NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_head.
- NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_assertion wasGeneratedBy ECO_0000203 NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_provenance.
- NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_assertion wasDerivedFrom befree-20150227 NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_provenance.
- NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_assertion SIO_000772 24577808 NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_provenance.
- NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_assertion evidence source_evidence_literature NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_provenance.
- NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_assertion description "[Although clinical trials have been performed with anti-IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308467.RAsk5Wel9uQ5MNSpbpSeqRl1IzkYzGlhBrEBawPO3aWVU130_provenance.